{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:04:15Z","timestamp":1790665455004,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40265-019-01068-2","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T13:22:35Z","timestamp":1550150555000},"page":"347-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Ravulizumab: First Global Approval"],"prefix":"10.1007","volume":"79","author":[{"given":"Kate","family":"McKeage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"1068_CR1","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","volume":"3","author":"A Hill","year":"2017","unstructured":"Hill A, DeZern AE, Kinoshita T, et al. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028.","journal-title":"Nat Rev Dis Primers."},{"issue":"4","key":"1068_CR2","doi-asserted-by":"publisher","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018;13(4):e0195909.","journal-title":"PLoS One"},{"key":"1068_CR3","unstructured":"Alexion Pharmaceuticals. FDA grants orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) [media release]. Jan 6 2017."},{"key":"1068_CR4","unstructured":"Alexion Pharmaceuticals. Comprehensive positive phase 3 data For Alexion\u2019s ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria presented at American Society Of Hematology (ASH) annual meeting and published in Blood [media release]. Dec 3 2018."},{"key":"1068_CR5","unstructured":"Alexion Pharmaceuticals. Alexion submits application for priority review and approval of ALXN1210 as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) in the U.S [media release]. June 19 2018."},{"key":"1068_CR6","unstructured":"US Food and Drug Administration. FDA approves ravulizumab-cwvz for paroxysmal nocturnal hemoglobinuria [media release] [media release]. Dec 21 2018. \n                    https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm629088.htm\n                    \n                  ."},{"key":"1068_CR7","unstructured":"Alexion Pharmaceuticals Inc. ULTOMIRIS\u2122 (Ravulizumab-cwvz): US Prescribing Information. 2018. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761108s000lbl.pdf\n                    \n                  . Accessed Jan 7 2019."},{"key":"1068_CR8","unstructured":"Alexion Pharmaceuticals. Alexion submits application for approval of ALXN1210 as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) in the European Union (EU) [media release]. June 28 2018."},{"key":"1068_CR9","unstructured":"Alexion Pharmaceuticals. Alexion initiates simultaneous registration trials of ALXN1210 for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) [media release]. Oct 27 2016."},{"key":"1068_CR10","unstructured":"Alexion Pharmaceuticals. Alexion reports second quarter 2017 results [media release]. July 27 2017."},{"key":"1068_CR11","unstructured":"Alexion Pharmaceuticals. Alexion reports second quarter 2018 results [media release]. July 26 2018."},{"key":"1068_CR12","unstructured":"Xencor. Xencor reports fourth quarter and full year 2013 financial results [media release]. Mar 19 2014."},{"key":"1068_CR13","unstructured":"Alexion Pharmaceuticals, Halozyme Therapeutics. Alexion and Halozyme enter license agreement for ENHANZE technology [media release]. Dec 7 2017."},{"key":"1068_CR14","unstructured":"Chugai Pharmaceutical. Chugai files lawsuit against Alexion for infringement of its proprietary antibody engineering technology in the U.S. [media release]. Nov 16 2018."},{"key":"1068_CR15","unstructured":"Chugai Pharmaceutical. Chugai files lawsuit against Alexion for infringement of its proprietary antibody engineering technology in Japan [media release]. Dec 5 2018."},{"key":"1068_CR16","unstructured":"Alexion Pharmaceuticals. Soliris\u00ae (eculizumab): US prescribing information. 2011. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125166s172lbl.pdf\n                    \n                  . Accessed 1 Feb 2019."},{"key":"1068_CR17","unstructured":"Alexion Pharmaceuticals. Soliris (eculizumab): EU summary of product characteristics. 2012. \n                    https:\/\/www.ema.europa.eu\/documents\/product-information\/soliris-epar-product-information_en.pdf\n                    \n                  . Accessed 1 Feb 2019."},{"key":"1068_CR18","doi-asserted-by":"crossref","unstructured":"De Latour RP, Brodsky RA, Ortiz S, et al. Ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: pharmacokinetics and pharmacodynamics observed in two phase 3 randomized, multicenter studies [abstract no. 626]. Blood. 2018;132(Suppl. 1).","DOI":"10.1182\/blood-2018-99-110858"},{"key":"1068_CR19","doi-asserted-by":"publisher","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2018. \n                    https:\/\/doi.org\/10.1182\/blood-2018-09-876136\n                    \n                  .","DOI":"10.1182\/blood-2018-09-876136"},{"key":"1068_CR20","doi-asserted-by":"publisher","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2018. \n                    https:\/\/doi.org\/10.1182\/blood-2018-09-876805\n                    \n                  .","DOI":"10.1182\/blood-2018-09-876805"},{"key":"1068_CR21","unstructured":"Alexion Pharmaceuticals. Alexion announces positive top-line results from phase 3 study of ULTOMIRIS\u2122 (ravulizumab-cwvz) in complement inhibitor-na\u00efve patients with atypical Hemolytic Uremic Syndrome (aHUS) [media release]. Jan 28 2019. \n                    https:\/\/news.alexion.com\/press-release\/product-news\/alexion-announces-positive-top-line-results-phase-3-study-ultomiris-ravul\n                    \n                  ."},{"issue":"17","key":"1068_CR22","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/bloodadvances.2018020644","volume":"2","author":"A Roth","year":"2018","unstructured":"Roth A, Rottinghaus ST, Hill A, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b\/2 studies. Blood Adv. 2018;2(17):2176\u201385.","journal-title":"Blood Adv."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01068-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01068-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01068-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:05:21Z","timestamp":1581638721000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01068-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01068-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"14 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Kate McKeage is a contracted employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}